Teva Pharmaceutical Industries’ TEVA late-stage study evaluating Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric and adolescent patients met its primary efficacy endpoint.

Treatment with fremanezumab led to a significantly greater reduction in monthly migraine days and monthly headache days. The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) ...

The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic ...

The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...

Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts. On June 24, Teva Pharmaceutical announced the final analysis results from its PEARL Phase ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...